Increase in the Risk of ST Elevation Myocardial Infarction Is Associated With Homocysteine Level

Basit Öğe Kaydı
dc.authoridAkyurek, Omer/0000-0001-6737-3686
dc.contributor.authorAkyurek, Omer
dc.contributor.authorAkbal, Erdem
dc.contributor.authorGunes, Fahri
dc.date.accessioned2025-01-27T20:29:36Z
dc.date.available2025-01-27T20:29:36Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground and Aims. The present study aimed to investigate the relationship between coagulation defects and ST elevation myocardial infarction (STEMI) in patients without any known coronary artery risk factors and considered low risk according to the Framingham risk classification. Methods. This study included 76 (73.6% male) STEMI patients without any known risk factors for coronary artery disease and 56 healthy controls (67.8% male) with similar characteristics. Results. Factor V Leiden mutation was noted in two patients and in one control. There were no significant differences in protein C, protein S, or antithrombin 3 values between the patient and control groups (p = 0.405, p = 0.476, and p = 0.221, respectively). None of the participants had antiphospholipid syndrome, factor V deficiency, or factor VII deficiency. Plasma homocysteine level was significantly higher in the patient group (19.0 +/- 3.6) mu mol/L than in the control group (15.8 +/- 4.2) mu mol/L (p = 0.008). Homocysteine levels in both groups were higher in males without a statistically significant difference. Vitamin B12 and folate levels, which are directly related to homocysteine metabolism, did not differ significantly between groups. Correlation analysis showed that the homocysteine level was not correlated with lipid parameters, folate, or vitamin B12. Conclusion. Homocysteine level was significantly higher in acute MI in patients without any risk factors and were considered low risk according to the Framingham risk score. The findings support the hypothesis that homocysteine level may be an independent risk factor for coronary artery disease. (C) 2014 IMSS. Published by Elsevier Inc.
dc.identifier.doi10.1016/j.arcmed.2014.08.003
dc.identifier.endpage506
dc.identifier.issn0188-4409
dc.identifier.issn1873-5487
dc.identifier.issue6
dc.identifier.pmid25193877
dc.identifier.scopus2-s2.0-84908074829
dc.identifier.scopusqualityQ1
dc.identifier.startpage501
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2014.08.003
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22992
dc.identifier.volume45
dc.identifier.wosWOS:000342548200009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofArchives of Medical Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectSTEMI
dc.subjectHomocysteine
dc.titleIncrease in the Risk of ST Elevation Myocardial Infarction Is Associated With Homocysteine Level
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu